文献速递肝病消化道肿瘤与早癌

丙型肝炎病毒诱导的表观遗传改变与肝癌风险相关,在持续病毒学应答后持续存在

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
PubMed 文献 · Gastroenterology · 2019-03-02

研究对6例无HCV感染对照、18例慢性HCV感染、8例DAA治愈、13例干扰素治愈、4例慢性HBV感染和7例非酒精性脂肪性肝炎患者的肝组织进行全基因组ChIPmentation ChIP-Seq和RNA-seq分析,并在人源化肝脏小鼠中验证。发现慢性HCV感染诱导特异性H3K27ac全基因组改变,这些改变在DAA或干扰素治疗获得SVR后持续存在,且与肝癌风险相关,SPHK1表达升高与HCC风险相关。

要点

  • 慢性HCV感染诱导特异性H3K27ac全基因组改变,与mRNA和蛋白质表达变化相关。
  • 这些表观遗传改变在DAA或干扰素治疗获得SVR后持续存在。
  • HCV诱导的表观遗传改变与肝癌风险相关,SPHK1表达升高与HCC风险相关。

核心结论

  • 在获得或未获得DAA治疗SVR的患者肝组织分析中,识别出与HCC风险相关的表观遗传和基因表达改变,这些改变或可靶向用于预防HCV感染治疗患者的肝癌。

研究设计与样本

  • 对6例无HCV感染对照、18例慢性HCV感染、8例DAA治愈、13例干扰素治愈、4例慢性HBV感染和7例非酒精性脂肪性肝炎患者的肝组织进行全基因组ChIPmentation ChIP-Seq和RNA-seq分析。
  • 使用uPA/SCID小鼠移植人肝细胞构建人源化肝脏小鼠,注射HCV感染患者血清,并给予DAA清除病毒。
  • 在8例DAA治疗获得SVR患者的配对HCC组织中进行验证分析。
  • 在216例HCV相关肝硬化患者(其中21例实现病毒清除)的独立队列中验证。

主要发现

  • 慢性HCV感染诱导特异性H3K27ac全基因组改变,与mRNA和蛋白质表达变化相关。
  • 这些改变在DAA或干扰素治疗获得SVR后持续存在。
  • 患者和人源化肝脏小鼠肝组织的整合通路分析显示,HCV诱导的表观遗传改变与肝癌风险相关。
  • 计算分析显示SPHK1表达升高与HCC风险相关。
  • 在216例HCV相关肝硬化患者(其中21例实现病毒清除)的独立队列中验证了上述发现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is an important risk factor for hepatocellular carcinoma (HCC). Despite effective antiviral therapies, the risk for HCC is decreased but not eliminated after a sustained virologic response (SVR) to direct-acting antiviral (DAA) agents, and the risk is higher in patients with advanced fibrosis. We investigated HCV-induced epigenetic alterations that might affect risk for HCC after DAA treatment in patients and mice with humanized livers. METHODS: We performed genome-wide ChIPmentation-based ChIP-Seq and RNA-seq analyses of liver tissues from 6 patients without HCV infection (controls), 18 patients with chronic HCV infection, 8 patients with chronic HCV infection cured by DAA treatment, 13 patients with chronic HCV infection cured by interferon therapy, 4 patients with chronic hepatitis B virus infection, and 7 patients with nonalcoholic steatohepatitis in Europe and Japan. HCV-induced epigenetic modifications were mapped by comparative analyses with modifications associated with other liver disease etiologies. uPA/SCID mice were engrafted with human hepatocytes to create mice with humanized livers and given injections of HCV-infected serum samples from patients; mice were given DAAs to eradicate the virus. Pathways associated with HCC risk were identified by integrative pathway analyses and validated in analyses of paired HCC tissues from 8 patients with an SVR to DAA treatment of HCV infection. RESULTS: We found chronic HCV infection to induce specific genome-wide changes in H3K27ac, which correlated with changes in expression of mRNAs and proteins. These changes persisted after an SVR to DAAs or interferon-based therapies. Integrative pathway analyses of liver tissues from patients and mice with humanized livers demonstrated that HCV-induced epigenetic alterations were associated with liver cancer risk. Computational analyses associated increased expression of SPHK1 with HCC risk. We validated these findings in an independent cohort of patients with HCV-related cirrhosis (n = 216), a subset of which (n = 21) achieved viral clearance. CONCLUSIONS: In an analysis of liver tissues from patients with and without an SVR to DAA therapy, we identified epigenetic and gene expression alterations associated with risk for HCC. These alterations might be targeted to prevent liver cancer in patients treated for HCV infection.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hamdane N, Jühling F, Crouchet E, et al. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. 2019. PMID: 30836093. doi:10.1053/j.gastro.2019.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。